New IMS Cure Definition Underscores Critical Role of Sensitive MRD Testing, Bolstering Adaptive's clonoSEQ Positioning

What happened

The International Myeloma Society and International Myeloma Working Group presented a new consensus definition of cure for multiple myeloma at their annual meeting, which for the first time formally incorporates highly sensitive minimal residual disease (MRD) testing. Adaptive Biotechnologies highlighted that its FDA-authorized clonoSEQ assay, with sensitivity down to 1 in 1,000,000 cells, is well positioned to meet the stringent MRD criteria embedded in the new definition. This development represents a significant advancement in clinical guidelines, as it elevates MRD from a prognostic tool to a component of the cure definition, likely accelerating its adoption in routine patient management. The news reinforces the company's core MRD franchise, which already benefits from broad Medicare coverage and growing biopharma demand following the ODAC endorsement of MRD as a surrogate endpoint. While the press release is self-promotional, the underlying consensus from a major medical society provides an independent validation of the clinical importance of highly sensitive MRD testing, a key pillar of Adaptive's growth strategy.

Implication

Investors should view this consensus as a durable tailwind that expands the addressable market for clonoSEQ, as hematologists may now feel compelled to use highly sensitive MRD testing to assess cure status. The inclusion of MRD in the cure definition is likely to drive increased testing volumes across both academic and community settings, especially given Adaptive's EHR integrations and broad reimbursement. However, it is important to recognize that guideline adoption and practice changes take time, and the immediate financial impact may be gradual rather than sudden. The development adds to the growing body of evidence supporting MRD's role, which strengthens the investment thesis but does not eliminate key risks such as reimbursement policy changes or competitive pressures. Overall, the news reinforces our BUY stance, as it enhances the long-term growth prospects for the MRD segment while aligning with management's focus on achieving MRD profitability in 2025.

Thesis delta

The new IMS definition of cure incorporating MRD testing represents a positive shift in the clinical landscape, directly strengthening the foundation of Adaptive's MRD growth strategy. This consensus adds to the existing regulatory and clinical tailwinds, increasing the probability of sustained clonoSEQ volume growth and market penetration. Consequently, our confidence in the durability of the MRD franchise is modestly increased, though we maintain our monitoring of reimbursement stability and execution on the path to profitability.